Solana (HSDT) Fundamentals 2026 — Revenue Analysis | SniperIQ
Solana (HSDT) is a US-listed Healthcare company in Medical - Devices with a market capitalization of
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Solana's market cap?
Solana (HSDT) has a market capitalization of approximately
What is Solana's P/E ratio?
Solana's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Solana?
Solana runs a net profit margin of -1427.1%, a gross margin of 94.2%, and an operating margin of -196.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Solana generate?
Solana reported revenue of $6M for fiscal year 2025, with net income of -$41M and earnings per share (EPS) of -1.85. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Solana pay a dividend?
Solana does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Solana financially healthy?
Solana carries a debt-to-equity ratio of 0.00x and a current ratio of 9.90x, with a market beta of 1.03. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Solana a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Solana (HSDT) the key facts are: market cap
Track Solana's full fundamentals live
Get Solana's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.